Charles River Laboratories Free Cash Flow 2010-2024 | CRL
Charles River Laboratories annual/quarterly free cash flow history and growth rate from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Charles River Laboratories free cash flow for the quarter ending December 31, 2024 was 501.61, a year-over-year.
- Charles River Laboratories free cash flow for the twelve months ending December 31, 2024 was , a year-over-year.
- Charles River Laboratories annual free cash flow for 2024 was $0.502B, a 37.29% increase from 2023.
- Charles River Laboratories annual free cash flow for 2023 was $0.365B, a 23.89% increase from 2022.
- Charles River Laboratories annual free cash flow for 2022 was $0.295B, a 44.57% decline from 2021.
| Charles River Laboratories Annual Free Cash Flow | |
|---|---|
| 2024 | 501.61 |
| 2023 | 365.37 |
| 2022 | 294.91 |
| 2021 | 532.03 |
| 2020 | 380.02 |
| 2019 | 340.42 |
| 2018 | 301.09 |
| 2017 | 235.64 |
| 2016 | 261.61 |
| 2015 | 243.58 |
| 2014 | 195.21 |
| 2013 | 169.89 |
| 2012 | 160.47 |
| 2011 | 157.70 |
| 2010 | 125.38 |
| 2009 | 135.72 |
| Charles River Laboratories Quarterly Free Cash Flow | |
|---|---|
| 2024-12-31 | 501.61 |
| 2024-09-30 | 417.86 |
| 2024-06-30 | 204.79 |
| 2024-03-31 | 50.74 |
| 2023-12-31 | 365.37 |
| 2023-09-30 | 222.75 |
| 2023-06-30 | 83.25 |
| 2023-03-31 | 2.51 |
| 2022-12-31 | 294.91 |
| 2022-09-30 | 149.17 |
| 2022-06-30 | 88.79 |
| 2022-03-31 | 22.17 |
| 2021-12-31 | 532.03 |
| 2021-09-30 | 401.54 |
| 2021-06-30 | 282.36 |
| 2021-03-31 | 142.20 |
| 2020-12-31 | 380.02 |
| 2020-09-30 | 329.49 |
| 2020-06-30 | 178.38 |
| 2020-03-31 | 42.87 |
| 2019-12-31 | 340.42 |
| 2019-09-30 | 223.58 |
| 2019-06-30 | 102.90 |
| 2019-03-31 | -1.87 |
| 2018-12-31 | 301.09 |
| 2018-09-30 | 229.79 |
| 2018-06-30 | 134.98 |
| 2018-03-31 | 32.33 |
| 2017-12-31 | 235.64 |
| 2017-09-30 | 139.91 |
| 2017-06-30 | 102.44 |
| 2017-03-31 | 18.11 |
| 2016-12-31 | 261.61 |
| 2016-09-30 | 168.64 |
| 2016-06-30 | 105.92 |
| 2016-03-31 | 37.59 |
| 2015-12-31 | 243.58 |
| 2015-09-30 | 150.89 |
| 2015-06-30 | 73.05 |
| 2015-03-31 | 0.60 |
| 2014-12-31 | 195.21 |
| 2014-09-30 | 122.38 |
| 2014-06-30 | 64.93 |
| 2014-03-31 | 17.27 |
| 2013-12-31 | 169.89 |
| 2013-09-30 | 121.23 |
| 2013-06-30 | 62.72 |
| 2013-03-31 | 23.55 |
| 2012-12-31 | 160.47 |
| 2012-09-30 | 109.88 |
| 2012-06-30 | 59.09 |
| 2012-03-31 | 11.17 |
| 2011-12-31 | 157.70 |
| 2011-09-30 | 113.27 |
| 2011-06-30 | 73.25 |
| 2011-03-31 | 14.60 |
| 2010-12-31 | 125.38 |
| 2010-09-30 | 73.92 |
| 2010-06-30 | 66.22 |
| 2010-03-31 | 18.64 |
| 2009-12-31 | 135.72 |
| 2009-09-30 | 91.75 |
| 2009-06-30 | 62.24 |
| 2009-03-31 | 12.49 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $8.719B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $150.904B | 28.19 |
| Elevance Health (ELV) | United States | $87.590B | 11.69 |
| CVS Health (CVS) | United States | $79.455B | 11.63 |
| Cencora (COR) | United States | $47.362B | 17.19 |
| DiDi Global (DIDIY) | China | $23.670B | 0.00 |
| Natera (NTRA) | United States | $20.908B | 0.00 |
| ICON (ICLR) | Ireland | $16.429B | 14.61 |
| Revvity (RVTY) | United States | $13.985B | 23.45 |
| BioMerieux (BMXMF) | France | $13.758B | 0.00 |
| Viatris (VTRS) | United States | $13.595B | 4.19 |
| Doximity (DOCS) | United States | $13.537B | 70.40 |
| Solventum (SOLV) | United States | $13.178B | 0.00 |
| Avantor (AVTR) | United States | $11.895B | 17.47 |
| CochLear (CHEOY) | Australia | $11.072B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.491B | 27.26 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $9.952B | 0.00 |
| HealthEquity (HQY) | United States | $9.484B | 47.58 |
| Sonic Healthcare (SKHHY) | Australia | $8.501B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $6.224B | 31.72 |
| Bausch + Lomb (BLCO) | Canada | $5.573B | 25.50 |
| Organon (OGN) | United States | $3.884B | 3.96 |
| Sotera Health (SHC) | United States | $3.814B | 20.40 |
| BrightSpring Health Services (BTSG) | United States | $3.382B | 71.93 |
| Surgery Partners (SGRY) | United States | $3.198B | 36.46 |
| Concentras Parent (CON) | United States | $2.951B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.613B | 0.00 |
| GeneDx Holdings (WGS) | United States | $2.610B | 316.67 |
| Ardent Health Partners (ARDT) | United States | $2.014B | 0.00 |
| PACS (PACS) | United States | $1.980B | 0.00 |
| Progyny (PGNY) | United States | $1.961B | 39.71 |
| Teladoc Health (TDOC) | United States | $1.961B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.845B | 48.40 |
| Premier (PINC) | United States | $1.690B | 10.82 |
| Agilon Health (AGL) | United States | $1.500B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.409B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.346B | 11.28 |
| CareDx (CDNA) | United States | $1.146B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $1.026B | 8.12 |
| Establishment Labs Holdings (ESTA) | $0.986B | 0.00 | |
| Embecta (EMBC) | United States | $0.798B | 5.47 |
| Auna S.A (AUNA) | Luxembourg | $0.598B | 0.00 |
| SBC Medicals (SBC) | United States | $0.484B | 0.00 |
| MultiPlan (MPLN) | United States | $0.472B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.472B | 0.00 |
| DocGo (DCGO) | United States | $0.453B | 17.08 |
| InnovAge Holding (INNV) | United States | $0.449B | 0.00 |
| Enhabit (EHAB) | United States | $0.406B | 35.09 |
| QDM (QDMI) | Hong Kong, SAR China | $0.335B | 8.78 |
| Nutex Health (NUTX) | United States | $0.314B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.253B | 0.00 |
| LifeMD (LFMD) | United States | $0.248B | 0.00 |
| Beauty Health (SKIN) | United States | $0.194B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.193B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.140B | 0.00 |
| Biodesix (BDSX) | United States | $0.122B | 0.00 |
| So-Young (SY) | China | $0.116B | 19.63 |
| Ascend Wellness Holdings (AAWH) | United States | $0.086B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.078B | 0.00 |
| ModivCare (MODV) | United States | $0.071B | 3.85 |
| Oncology Institute (TOI) | United States | $0.064B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 1.61 |
| OncoCyte (OCX) | United States | $0.046B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.035B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.020B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.015B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.014B | 0.00 |
| KindlyMD (KDLY) | United States | $0.013B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.007B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| XWELL (XWEL) | United States | $0.006B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |